Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients
Nemunaitis J, Cunningham C, Senzer N, Kuhn J, Cramm J, Litz C, Cavagnolo R, Cahill A, Clairmont C, Sznol M. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Therapy 2003, 10: 737-744. PMID: 14502226, DOI: 10.1038/sj.cgt.7700634.Peer-Reviewed Original ResearchConceptsE. coli cytosine deaminase geneCytosine deaminase geneRefractory cancer patientsTAPET-CDCancer patientsPilot trialIntratumoral injectionSignificant adverse eventsCycles of treatmentProgression of diseaseSalmonella bacteriumIntolerable toxicityAdverse eventsPatientsDays p.Dose levelsDay 4Initial injectionSystemic spreadDeaminase geneMalignant tissuesBacterial colonizationCFU/m2TumorsDay cycle